Asthma Reliever Therapies

DRUG3 trials

Sponsors

Sanofi

Conditions

Asthma

Phase 3

Evaluation of Dupilumab in Children With Uncontrolled Asthma

CompletedNCT02948959

Start: 2017-04-21End: 2020-08-26Updated: 2022-03-28

Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)

CompletedNCT03560466

Start: 2018-06-21End: 2025-04-01Updated: 2025-11-21

Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma

CompletedNCT03782532

Start: 2019-01-25End: 2022-05-21Updated: 2022-12-28

Related Papers

Dupilumab efficacy by disease severity in pediatric type 2 asthma.

2025-11-011 citations

Dupilumab Plus Medium‐Dose Inhaled Corticosteroid (ICS) Improves Outcomes Compared With Placebo Plus Continued High‐Dose ICS in Children With Uncontrolled Moderate‐to‐Severe Type 2 Asthma

Pediatric Pulmonology2025-07-012 citations

Dupilumab Reduces Exacerbations and Improves Asthma Control in Children Regardless of Asthma Duration

American Journal of Respiratory and Critical Care Medicine2025-05-01

Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia–Pacific Region

Clinical & Experimental Allergy2025-02-232 citations

Dupilumab Efficacy and Safety in Children With Moderate to Severe Asthma and High Blood Eosinophils: A Post Hoc Analysis of VOYAGE.

2024-11-283 citations

Dupilumab Efficacy in Children With Type 2 Asthma Receiving High- to Medium-Dose Inhaled Corticosteroids (VOYAGE).

2024-08-285 citations

Dupilumab 200 mg was efficacious in children (6–11 years) with moderate‐to‐severe asthma for up to 2 years: EXCURSION open‐label extension study

Pediatric Pulmonology2024-07-174 citations

OP-059 Lung function improvement by dupilumab associated with better asthma control in children

2024-07-01

Impact of Exacerbation History on Dupilumab Efficacy in Children with Uncontrolled Moderate-to-Severe Asthma: LIBERTY ASTHMA VOYAGE Study.

2024-03-051 citations

Long-term dupilumab effect on lung function in paediatric patients with uncontrolled asthma

Pneumologie2024-03-01

Fractional exhaled nitric oxide as a biomarker in patients with uncontrolled asthma

Pneumologie2024-03-01

Impact of Lung Function on Asthma Exacerbation Rates in Children Treated with Dupilumab: The VOYAGE Study

Journal of Asthma and Allergy2024-02-013 citations

Dupilumab long term efficacy in children with moderate-to-severe type 2 asthma with/without evidence of allergic asthma

Klinische Pädiatrie2024-02-01

Improved lung function is associated with better asthma control in children aged 6 to 11 years with moderate-to-severe type 2 asthma: A post hoc analysis of VOYAGE

Klinische Pädiatrie2024-02-01

Long-term dupilumab effect on lung function in paediatric patients with uncontrolled asthma

Klinische Pädiatrie2024-02-01

Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma

Journal of Allergy and Clinical Immunology2024-01-2342 citations

Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study.

2023-12-1110 citations

Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study.

2023-11-1027 citations

P124 Stability of fractional exhaled nitric oxide levels as a biomarker in patients with uncontrolled asthma

2023-11-01

Long-term dupilumab effect on lung function in paediatric patients with uncontrolled asthma

2023-09-09

15 more papers not shown